John Kollins, Satsuma Pharmaceuticals CEO
April 17, 2023 07:18 AM EDT
Deals

Japan­ese CRO buys back pen­ny stock spin­out while await­ing FDA de­ci­sion on mi­graine can­di­date

Amber Tong

Months af­ter an­nounc­ing it will not take on the com­mer­cial­iza­tion of its own mi­graine drug-de­vice, Sat­suma Phar­ma­ceu­ti­cals has found the buy­er …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump picks vac­cine skep­tic Kennedy to lead HHS, in what would be an up­heaval of US health pol­i­cy

BeiGene will re­brand to BeOne Med­i­cines, drop­ping name's link to Chi­na roots

Eu­ro­pean drug reg­u­la­tor re­vers­es opin­ion on Ei­sai and Bio­gen's Alzheimer's drug

Gilead will close Philadel­phia, Seat­tle of­fices as part of job re­duc­tions

Mer­ck buys in­to PD-1/VEGF space as Sum­mit comes for Keytru­da

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times